Rilpivirine
- TRADE NAMES: Complera (Gilead); Edurant (Centocor); Juluca (ViiV)
- INDICATIONS: HIV-1 infection
- CLASS: Antiretroviral, Non-nucleoside reverse transcriptase inhibitor
- HALF-LIFE: 50 hours
FDA APPROVAL DATE: 06/10/2011
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Antacids, Atazanavir, Carbamazepine, Cimetidine, Clarithromycin, Darunavir, Delavirdine, Dexamethasone, Efavirenz, Erythromycin, Esomeprazole, Etravirine, Famotidine, Fluconazole, Fosamprenavir, Indinavir, Itraconazole, Ketoconazole, Lansoprazole, Lopinavir, Methadone, Nelfinavir, Nevirapine, Nizatidine, Ombitasvir/Paritaprevir/Ritonavir, Omeprazole, Oxcarbazepine, Pantoprazole, Phenobarbital, Phenytoin, Posaconazole, QT prolonging agents, Rabeprazole, Ranitidine, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Tipranavir, Troleandomycin, Voriconazole
PREGNANCY CATEGORY: B
Complera is rilpivirine, emtricitabine and tenofovir; Juluca is rilpivirine and dolutegravir.
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
